三星否认溢价收购百健
. 三星否认溢价收购百健(BIIB.US)
智通财经APP获悉，12月30日，三星集团旗下的三星生物(Samsung Biologics)(KS:207940)表示，有关其正在洽谈收购百健(NASDAQ:BIIB)的报道不属实。
据悉，此前有媒体报道称，三星集团正在洽谈收购百健。报道称，百健已与三星接洽出售其股票的事宜，该公司的估值可能超过50万亿韩元(约420亿美元)，较百健市值溢价逾10%。受该消息提振，百健周三收涨近10%。
More Stories
Oil inches higher as Middle East tensions heat up
© Reuters. Army soldier miniatures and stock graph are seen in this illustration taken October 9, 2023. REUTERS/Dado Ruvic/Illustration/File Photo...
Asian stocks rise before US CPI; Japan’s Nikkei extends rally
. JP225 +1.88% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully to: + Add another position...
SEC approves spot Bitcoin ETFs
. SEC approves spot bitcoin ETFs BTC/USD +1.76% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully...
Google lays off hundreds in Assistant, hardware, engineering teams
© Reuters. The Google logo is seen on the Google house at CES 2024, an annual consumer electronics trade show,...
US SEC approves bitcoin ETFs in watershed for crypto market
© Reuters. FILE PHOTO: FILE PHOTO: U.S. Securities and Exchange Commission logo and representations of cryptocurrency are seen in this...
Amazon has not offered remedies to EU concerns over iRobot deal
© Reuters. FILE PHOTO: The logo of Amazon is seen at the company's logistics centre in Boves, France, October 6,...